1. Home
  2. FSBW vs CAPR Comparison

FSBW vs CAPR Comparison

Compare FSBW & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSBW
  • CAPR
  • Stock Information
  • Founded
  • FSBW 1936
  • CAPR 2005
  • Country
  • FSBW United States
  • CAPR United States
  • Employees
  • FSBW N/A
  • CAPR N/A
  • Industry
  • FSBW Banks
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FSBW Finance
  • CAPR Health Care
  • Exchange
  • FSBW Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • FSBW 324.8M
  • CAPR 324.6M
  • IPO Year
  • FSBW 2012
  • CAPR N/A
  • Fundamental
  • Price
  • FSBW $42.71
  • CAPR $6.28
  • Analyst Decision
  • FSBW Hold
  • CAPR Strong Buy
  • Analyst Count
  • FSBW 1
  • CAPR 8
  • Target Price
  • FSBW $44.00
  • CAPR $24.75
  • AVG Volume (30 Days)
  • FSBW 17.5K
  • CAPR 1.4M
  • Earning Date
  • FSBW 10-21-2025
  • CAPR 08-11-2025
  • Dividend Yield
  • FSBW 2.62%
  • CAPR N/A
  • EPS Growth
  • FSBW N/A
  • CAPR N/A
  • EPS
  • FSBW 4.15
  • CAPR N/A
  • Revenue
  • FSBW $139,676,000.00
  • CAPR $13,392,150.00
  • Revenue This Year
  • FSBW $9.62
  • CAPR N/A
  • Revenue Next Year
  • FSBW $5.35
  • CAPR $6,061.53
  • P/E Ratio
  • FSBW $10.28
  • CAPR N/A
  • Revenue Growth
  • FSBW 0.61
  • CAPR N/A
  • 52 Week Low
  • FSBW $34.61
  • CAPR $3.98
  • 52 Week High
  • FSBW $49.15
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • FSBW 61.80
  • CAPR 36.33
  • Support Level
  • FSBW $41.40
  • CAPR $6.17
  • Resistance Level
  • FSBW $42.89
  • CAPR $7.30
  • Average True Range (ATR)
  • FSBW 1.14
  • CAPR 0.43
  • MACD
  • FSBW 0.32
  • CAPR -0.11
  • Stochastic Oscillator
  • FSBW 95.42
  • CAPR 4.53

About FSBW FS Bancorp Inc.

FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: